To test the hypothesis that muscarinic receptors are involved in the pathology of schizophrenia, we measured muscarinic 1 (M1R) and muscarinic 4 (M4R) protein and mRNA as well as ETE, P Ͻ 0.01) and BA 40 (28 ± 5.9 vs 99 ± 14, P Ͻ 0.01) with schizophrenia but M4R mRNA was only decreased in BA 40 (48 ± 6.6 vs 89 ± 9.9, P Ͻ 0.005). These data suggest that the M1R, at least in the dorsolateral prefrontal cortex, may have a role in the pathology of schizophrenia.
Introduction
It has been suggested that the cholinergic systems of the central nervous system (CNS) are involved in the pathology of schizophrenia. 1 This hypothesis is supported by a growing understanding that the deficits of CNS function associated with schizophrenia, such as cognitive function, memory, motor activity and sleep, 2 are significantly influenced by cholinergic systems. Interest in cholinergic systems in schizophrenia was reawakened with the demonstration that drugs such as clozapine and olanzapine, both of which bind to muscarinic receptors, 3 are of therapeutic benefit in treating symptoms of the disorder. 4, 5 Thus, from therapeutic pharmacology, postmortem tissue research and other lines of evidence it has now been suggested that muscarinic receptors are important in the pathology of schizophrenia. 2 Five muscarinic receptors have been identified in the human CNS 2 but investigations on the involvement of changes in muscarinic receptors in schizophrenia have been hampered by the lack of receptor-specific radioligands and drugs. 6 This laboratory has reported a decrease in [ 3 H]pirenzepine binding in the frontal cor-tex, 7, 8 hippocampus 9 and caudate-putamen 10 from subjects with schizophrenia. [ 3 H]pirenzepine binds selectively to muscarinic 1 (M1R) and muscarinic 4 (M4R) receptors 11 and we therefore suggested that deficits in M1R and/or M4R are present in various CNS regions from subjects with schizophrenia. Given the different roles for these receptors in the human CNS 2 it was important to determine the changes in M1R and M4R that were contributing to changes in [ 3 H]pirenzepine binding in the CNS of subjects with schizophrenia.
To begin to address the issue of which muscarinic receptors are altered in the CNS of subjects with schizophrenia, we focused on human cortex obtained postmortem. The cholinergic system innervates the entire cortex, but the input to the frontal cortex is more influenced by direct projections from the basal forebrain whilst cholinergic inputs into the parietal and occipital cortex are more modulated by the thalamus. 12 To determine if these differences in input could affect the status of M1R and M4R in cortical regions in schizophrenia, we measured [ 3 H]pirenzepine binding in Brodmann's area (BA) 9 (dorsolateral prefrontal cortex) and 40 (supramarginal area of the parietal lobe) obtained postmortem. In addition, to determine which of the two muscarinic receptors that bind [ 3 H]pirenzepine are altered in schizophrenia, we measured the levels of M1R and M4R by Western blots with receptor specific antibodies and levels of mRNA using in situ hybridisation.
Tissue collection
Consent for this study was obtained from the Ethics Committee of the Victorian Institute of Forensic Medicine and the North Western Mental Health Program Behavioural and Psychiatric Research and Ethics Committee. After gaining consent, blocks of tissue, containing BA 9 and 40 were excised from the left hemisphere of subjects who were listed as having schizophrenia in reports of death. Tissue was also collected from the same regions from subjects with no history of psychiatric illness (controls) who were matched for sex and closely matched for age to the subjects with schizophrenia (Tables 1 and 2 ). In cases where death was witnessed, the time between death and autopsy was taken as the postmortem interval (PMI). Where death was not witnessed, tissue was only taken from individuals who had been seen alive up to 5 h before being found dead. In these cases PMI was taken as the interval half way between the donor being found dead and last being seen alive. In all cases, cadavers were refrigerated within 5 h of being found and tissue was rapidly frozen to −70°C within 30 min of autopsy. The pH of the CNS tissue was measured as described previously. 13 
Diagnostic evaluation
For a subject to be included in this study, sufficient information needed to be available from clinical case records to enable a psychologist and psychiatrist to reach a diagnostic consensus using the Diagnostic Instrument for Brain Studies (DIBS). The DIBS is a semi-structured protocol for postmortem assessment 14 allowing the diagnosis of schizophrenia according to DSM-IV criteria. 15 Subjects with schizoaffective disorder were excluded. When available, postmortem toxicology was reviewed to exclude recent substance misuse and levels of antipsychotic and anticholinergic drugs in blood were recorded. Duration of illness (DOI) was calculated as the time from first admission to death and a comprehensive medication history was obtained for each subject. Most recently prescribed antipsychotic and anticholinergic drugs and their final record prescribed doses were recorded and then converted to standardised drug doses 16 (Tables 1 and 2) . 
Western blot analyses
Tissue for the analysis of M1R and M4R by Western blot was prepared from each block of BA 9 and BA 40 used to prepare frozen sections for in situ radioligand binding and in situ hybridisation. Each sample of tissue was homogenized with five strokes of a Teflonglass homogenizer into 20 mM TRIS-HCl pH 7.4 containing 0.2 mM EGTA and 0.1 mM EDTA. Importantly, 3 × CPIC, phenylmethylsulfonylfluoride (1 mM), leupeptin (10 g ml − ), benzamidine (1 mM), bacitracin (1 mg ml −1 ), pepstatin (10 g ml −1 ) and chymostatin (10 ); ND = not detected.
g ml −1 ) were added to the homogenisation buffer on the day of use. Homogenised tissue was stored on ice until the concentration of protein in each sample was measured using the BioRad protein assay and then frozen at −70°C until required.
Duplicate measurements of M1R and M4R were made for each sample and the samples from schizophrenics and their age-and sex-matched controls were run on the same gel. Thus, on the day of assay each tissue homogenate was thawed and the protein concentration adjusted to 1.0 mg ml
. A sample of each homogenate was than denatured by heating at 95°C for 4 min in an equal volume of electrophoresis buffer (0.5 M TRIS-HCl pH 6.8, containing 20% glycerol, 10% SDS, 10% 2-␤-mercaptoethanol and 0.05% bromophenol blue). The denatured tissue was then loaded onto 4% SDS stacking gel (20 g protein per well) and separated on 10% (M1R) or 7.5% (M4R) SDS mini-gels (200 V constant). Proteins were then transferred from the mini-gel to either Trans-blot 
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The proteins on each nitrocellulose and PVDF membrane were then stained with 0.2 % Ponceau S Red in 3% trichloroacetic acid to verify transfer had occurred. For the measurement of M1R, the nitrocellulose membranes containing the separated proteins were placed in blocking buffer A (Tween Tris buffered saline (TTBS: 100 mM Tris pH 7.5, 0.9% sodium chloride and 0.1% Tween 20) containing 5% blotting grade non-fat milk) for 45 min at room temperature (RT) with agitation. The proteins on the membrane were then exposed to anti-M1R antibody (diluted 1:1600) in blocking buffer A for 45 min at RT with agitation and then washed 6 × 5 min in TTBS. The washed membranes were exposed to 1: 2000 dilution Vector goat anti-rabbit IgG conjugated to horseradish peroxidase in blocking buffer A for 45 min at RT and then washed 6 ×5 min at RT with TTBS. Each membrane was then incubated with Amersham ECL  at RT for 60 s followed by exposure to Amersham Hyperfilm-ECL  so that the density of the internal control was within the previously defined optical density (OD) range (see below).
For the measurement of M4R, the PVDF membranes containing the separated proteins were placed in blocking buffer B (blocking buffer A containing 2% heat- The proteins on the membrane were then exposed to anti-M4R (diluted 1:500) in blocking buffer B for 4 h at RT with agitation and then washed 3 × 5 min in blocking buffer A. Each membrane was then exposed to 1:6000 dilution DAKO goat anti-rabbit IgG antibody conjugated to horseradish peroxidase in blocking buffer B for 2 h at RT and then washed 4 × 5 min at RT with blocking buffer A and twice with TTBS. PVDF membranes were then processed as described for nitrocellulose membranes to obtain an image on Amersham Hyperfilm-ECL  . All ECL film was developed in Kodak D-19 X-ray developer and fixed with Ilford Hypam X-ray fixer. When the ECL film was washed and dried, it was imaged with a digital CCD camera and the OD of the bands measured using an MCID image analysis system.
To control for blot-to-blot variation, a single membrane preparation (internal control) was initially prepared from BA 9 from a single donor. For both M1R and M4R measurements, this sample was run in all 15 wells on two gels (30 measurements) to establish the intra-and inter-gel variation in the measurement of M1R and M4R protein for the internal control. The internal control was subsequently run on every gel from which measurements of M1R or M4R protein were taken, with each gel being exposed to the ECL film for a time that allowed the OD of the internal control to fall within the range established, by calculating the mean ± two standard deviations of the initial 30 repeated measurements.
In situ hybridisation
All solutions for in situ hybridisation used 0.1% diethyl pyrocarbonate-treated water.
For in situ hybridisation, 6 × 10 m frozen tissue sections were cut from BA 9 and BA 40 from each subject at the same time as those cut for in situ radioligand binding. These sections were stored frozen at −70°C until required. On the day of assay, the frozen sections were removed from cold storage and dried for at least 1 h at RT. The sections were then placed in 4% paraformaldehyde in phosphate buffered saline (PBS: 136 mM NaCl, 2 mM KH 2 PO 4 , 1 mM Na 2 HPO 4 and 2.5 mM KCl) for 5 min at RT. The fixed sections were rinsed twice in PBS then placed in fresh 0.25% acetic anhydride in 0.1 M triethanolamine HCl, pH 8.0 for 10 min at RT, dehydrated by transfer through ethanol, delipidated in chloroform and equilibrated into 95% ethanol before being dried at RT.
As in an earlier study, 17 to increase hybridisation specificity each oligonucleotide probe contained a mix of three antisense sequences that were designed to hybridise to three regions of the receptor specific mRNA. Thus, for the M1R the oligonucleotide probes were complimentary to bases 4-51, 721-768, 811-853 of the human m1 mRNA (accession No: X52068) whilst the M4R were complimentary to bases 4-51, 721-768, 789-839 of human m4 mRNA (accession No: NM000741). The probes were labelled with [
35 S]ATP using the NEN Oligonucleotide 3Ј end labeling system with each labelled probe being purified using a Micro Bio-Spin Bio Gel P30 column.
Prior to hybridisation with the tissue sections, 2 l of radiolabeled probe was placed into 4 ml scintillation fluid and the radioactivity of the probe measured. A sufficient quantity of probe was then prepared by dispersing the radiolabeled probe at 1 × 10 6 dpm of radioactivity per 50 l of hybridisation buffer (formamide (50%), NaCl (600 mM), Tris-HCl (80 mM), EDTA (4 mM), sodium pyrophosphate (0.1%), SDS (0.2%), sodium heparin (0.2 mg ml − ), dextran sulphate (10%) and DTT (100 mM) ), to give enough solution to cover all tissue sections. The radiolabeled probes were then incubated with tissue sections under optimized conditions to give maximum hybridisation (20 h at 37°C for M1R and M4R). To prevent dehydration each section was covered with parafilm and incubations were completed in a humidified chamber containing filter paper soaked in formamide (50%) in 4 × saline sodium citrate buffer (4 × SSC is diluted from a stock of 20 × SSC: 3 M NaCl plus 0.3 M Na citrate at pH 7.2). Two sections were incubated with the relevant radioactive oligonucleotide probe (total binding), whilst two sections were incubated with the radioactive oligonucleotide probe in the presence of an excess of non-radioactive probe (NSB). In addition, the specificity of oligonucleotide probe hybridisation to mRNA was confirmed by incubating two sections which had been exposed to RNase prior to hybridisation with the radioactive probes (negative control).
On completion of the hybridisation procedure, all tissue sections were washed as described previously. 18 The washed and dried sections were then apposed to Amersham Hyperfilm  -␤max along with [ 14 C]microscales  for a period sufficient to generate an image of appropriate density (ෂ6 weeks). Each image was then analysed as described for sections undergoing in situ radioligand binding. The specific binding of the oligonucleotide probes were calculated as total binding minus NSB expressed as dpm × 10 3 mg −1 ETE.
Statistical analysis
All sets of data were first analysed using the Kolmogorov-Smirnov test to determine whether they had a Gaussian distribution. Age, PMI and CNS pH for the two diagnostic cohorts were compared using Student's t-test. Two-way ANOVA was used to identify variations between diagnoses or CNS region in all experimental measures. Post-hoc analyses using Student's ttests were then used to identify the source of variation between diagnostic groups, CNS regions or between drug treatments within diagnostic groups. Pearson product-moment correlations, assuming a straight-line best fit, were used to determine if the experimental data were influenced by donor age, PMI, CNS pH, DOI or final recorded antipsychotic drug dose.
Results
Demographic data BA 9 and BA 40 were obtained from 14 male and six female schizophrenic and 14 male and six female control subjects (Table 2 ). There was no statistical difference in the mean age of the schizophrenic (mean ± SEM: 42 ± 3.0 yrs) and control (47 ± 3.2 yrs) subjects (P = 0.3). Similarly, there were no significant differences in CNS pH (6.24 ± 0.07 vs 6.23 ± 0.05; P = 0.87) or PMI (37.9 ± 2.6 vs 37.9 ± 3.0 h; P = 0.99). Due to restrictions on the availability of tissue, analysis in BA 40 could not be completed on tissue from one schizophrenic (ID 5) and one control (ID 29) subject. 
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showed that there was a significant variation in [ 3 H]pirenzepine binding between diagnoses (F = 7.45, df = 1,75, P = 0.01) which was not apparent between CNS regions (F = 2.15, df = 1,75, P = 0.15). Analysis with Student's t-test within CNS regions showed that this was due to a significant decrease in the density of [ 3 H]pirenzepine binding in BA 9 (151 ± 15 vs 195 ± 10 fmol mg −1 ETE; P Ͻ 0.02), but not BA 40 (143 ± 13 vs 166 ± 11 fmol mg −1 ETE; P = 0.18), from the subjects with schizophrenia (Figure 1b) .
Western blot analyses
The Western blots for the M1 and M4 receptor in human CNS were essentially as obtained with other human tissue using the same quality controlled commercially available antibodies (Figure 2a, c) . 19, 20 Thus, the protein bands representing the M1 and M4 receptors were identified by careful measurement of Rf values prior to quantification of the optical density values.
Two-way ANOVA showed there was significant variation in the levels of M1R protein with diagnoses (F = 3.88, df = 1.75, P = 0.05) and CNS region (F = 22.92, df = 1.75, P Ͻ 0.01) (Figure 2b ). Further analysis within diagnosis showed this was due to a decrease in M1R in BA9 (0.11 ± 0.007 vs 0.15 ± 0.008 OD; P Ͻ 0.01) but not BA 40 (0.10 ± 0.002 vs 0.09 ± 0.004 OD; P = 0.084) from subjects with schizophrenia. Analysis within diagnosis but between regions showed that the variance between regions was due to differences in levels of M1R in BA 9 and BA 40 (0.15 ± 0.008 vs 0.09 ± 0.004) from the control subjects (P Ͻ 0.01).
Two-way ANOVA showed no significant differences between M4R proteins with diagnosis (F = 0.9, df = 1.75, P = 0.35) or CNS region (F = 0.61, df = 1.75, P = 0.44) (Figure 2d ).
In situ hybridisation
After incubating for ෂ6 weeks images were obtained showing the distribution of mRNA for the M1R ( Figure  3a ) and M4R (Figure 3c ) in BA9 and BA 40 to be diffuse across laminae II-VI of the cortex. In the majority of cases, the image in the presence of either excess unlab- elled probe or from tissue exposed to RNase was not of sufficient intensity to analyse using the [ 14 C]microscales  . In those instances, total binding was taken as specific binding. In the remaining cases, binding of the radiolabelled probe to sections exposed to RNase or to sections along with cold labelled (NSB) was less than 10% of that of total binding. In these cases, the specific binding of the radiolabelled probe was calculated as total binding minus NSB. These data demonstrate that, in all cases, the radiolabelled probes were binding to mRNA with a sequence complimentary to that probe. Two-way ANOVA showed a significant difference in the levels of mRNA for the M1R with diagnoses (F = 29.2, df = 1.75, P Ͻ 0.001) but not between CNS regions (F = 0.73, df = 1.75, P = 0.39) (Figure 3b) . The difference in M1R mRNA with diagnosis was due to a significant decrease in mRNA in BA 9 (30 ± 7.0 vs 79 ± 14 dpm × 10 −3 mg −1 ETE, P Ͻ 0.01) and BA 40 (28 ± 5.9 vs 99 ± 14, P Ͻ 0.01) in the tissue from the subjects with schizophrenia. Two-way ANOVA also showed a significant variation in levels of mRNA for the M4R with diagnosis (F = 8.95, df = 1.75, P Ͻ 0.005) but not between CNS regions (F = 0.95, df = 1.75, P = 0.33) (Figure 3d ). The variance with diagnoses was due to a significant decrease in levels of mRNA encoding M4R in BA 40 from subjects with schizophrenia (48 ± 6.6 vs 89 ± 9.9, P Ͻ 0.005).
Molecular Psychiatry

Confounding factors
For both cohorts of subjects, there were no significant correlations between experimental variables in either CNS region with donor age (r with schizophrenia, there were no significant correlations between experimental variables and DOI illness (r 2 0.003-0.24). All the schizophrenic subjects from whom tissue had been obtained for this study had been treated with antipsychotic drugs, however, blood levels of drugs at autopsy were not detected in 16 of the 20 subjects (Table 1 ). There were no significant correlations between experimental variables and final recorded antipsychotic drug dose (r 2 0.01-0.18) in either CNS region. Measurable levels of antipsychotic drug were detected in the blood of only three individuals and Molecular Psychiatry hence a meaningful regression of this factor with the experimental variables could not be completed.
Another confounding factor was that six of the 20 schizophrenic subjects had a record in their case histories of receiving anticholinergic drugs close to death (Table 1) . However, the levels of anticholinergic drugs in blood from these individuals that was obtained at autopsy were too low to be measured. In neither CNS region was there a correlation between the final recorded dose of anticholinergic drug and any of the experimental variables (r 2 0.02-0.49).
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Discussion
As in earlier studies, 8, 21 ]-QNB) to muscarinic receptors has been reported in the frontal cortex of subjects with schizophrenia being treated with antipsychotic drugs until death. 22 There are several explanations for this apparent discrepancy, the most obvious being that our study uses a M1R/M4R selective ligand 11 with autoradiography, whilst the other uses a nonselective muscarinic receptor radioligand with particulate membrane. 22 Thus, differences between studies could be purely due to methodological variation. Alternatively, it is possible that increases in M2, M3 and/or M5 in BA 9 from schizophrenic subjects, that would not be detected with [ 3 H]pirenzepine, are of a sufficient order of magnitude to give an overall increase in [ 3 H]-QNB. 22 To understand the cause of the decrease in [ 3 H]pirenzepine binding in the cortex of subjects with schizophrenia, we measured M1 and M4R proteins using receptor-specific antibodies. These studies show there is a decrease in M1R in BA 9, but not BA 40, from subjects with schizophrenia whilst the levels of M4R are not changed in either region. These data suggest that decreases in [ 3 H]pirenzepine binding in BA 9 from subjects with schizophrenia reflect a reduction in M1R. The experimental design of our study does not allow a comparison of relative levels of M1R and M4R protein within BA 9 or BA 40. By contrast, an earlier study using immunoprecipitation of radiolabelled muscarinic receptors with receptor-specific antibodies 23 showed that M1R is the predominant muscarinic receptor in the human cortex. Unfortunately in the immunoprecipitation study, muscarinic receptors were only measured in one cortical region, so it is not possible to compare our results on variations of muscarinic receptors between cortical regions.
Our study has shown a decrease in M1R mRNA and [ 3 H]pirenzepine binding in BA 9 from subjects with schizophrenia. These findings contrast with our studies in the caudate-putamen where we showed there was a decrease in [ 3 H]pirenzepine binding 10 that was not associated with a decrease in levels of M1R mRNA. 17 Hence, further studies will be needed to identify the causes of changed [ 3 H]pirenzepine binding in other CNS regions in schizophrenia. Significantly, the decreases we have shown in M1R and M4R mRNA in BA 40 from subjects with schizophrenia are not accompanied by a decrease in receptor protein or radioligand binding. Dissociation between receptor mRNA levels and other measures of receptor protein have been reported previously 10, 17, 24 in studies using tissue obtained postmortem. It remains to be determined if changes in mRNA alone have physiological significant outcomes that would result in altered CNS function.
One confounding factor deserves consideration in relation to this study, which is that all individuals with schizophrenia from whom tissue was obtained for this study had a record of receiving antipsychotic drugs. Significantly, the absence of a relationship between any experimental measure and final recorded antipsychotic drug dose suggests that this confounding factor was not a significant contributor to the reduction of M1R in BA 9. A similar analysis suggests that antipsychotic drugs were not the cause of the reduction in M4R mRNA in both CNS regions studied. Moreover, [ 3 H]pirenzepine binding has been shown to be only marginally reduced (ෂ10%) in the cortex of rats treated for 4 weeks with haloperidol but not clozapine. 8 In that study, rats treated for longer periods (up to 7 months) had increased cortical [ 3 H]pirenzepine binding, a finding that is in line with the study of muscarinic receptors in schizophrenics receiving antipsychotic drugs at death. 22 Thus, available data would not support the hypothesis that differences relating to M1R and M4R in schizophrenia in this study are simply due antipsychotic drug treatment.
Unlike in our previous study, 8 this study did not find a significant difference in [ 3 H]pirenzepine binding in tissue from subjects who had a record of receiving anticholinergic drugs in their clinical history. Notably, none of the subjects in this study had detectable levels of anticholinergic drugs in their blood at autopsy, suggesting anticholinergic drugs were not administered close to death. Thus, it is possible that any effect of these drugs on [ 3 H]pirenzepine binding was no longer apparent.
Levels of M4R mRNA were decreased in both BA 9 and BA 40 from subjects with schizophrenia and hence a role for that receptor in the pathology of the illness cannot be excluded. However, the M4R protein was not altered in either cortical region and radioligand binding was normal in BA 40. Thus, despite the change in levels of mRNA for the M4R, the presence of normal levels of receptors in subjects with schizophrenia should nullify changes in M4R expression at the level of mRNA.
The decrease in M1R protein, mRNA and radioligand binding makes it likely there are changes in M1R function in BA 9 from subjects with schizophrenia. Importantly, the effects of a deficiency in M1R can now be studied in an M1R knockout mouse. 25 Studies in these mice have shown that deletion of the M1R leads to disturbances in learning, memory 25 and circadian rhythms. 26 Since these are functions that are all affected in subjects with schizophrenia 27, 28 it would seem that data from M1R knockout mice support the hypothesis that abnormalities in M1R could play a role in the pathology of the illness.
In this study, we examined two cortical regions to investigate whether M1R and M4R in the frontal cortex, which is more influenced by cholinergic projections from the basal forebrain, 12 may be more affected in schizophrenia. The localisation of changes in M1R to BA 9 is preliminary data to support this hypothesis. These findings support the hypothesis that drugs which target specific muscarinic receptors will be beneficial in treating the symptoms of schizophrenia. 29, 30 Further investigations of changes in specific muscarinic receptors in a larger number of cortical regions will be required to fully determine the regional specificity of changes in muscarinic receptors in schizophrenia.
